Dupixent(R) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Dupixent(R) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma GlobeNewswire December 23, 2025 Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic […]